argenx SE American Depositary Shares

Argenx discontinued its Phase 3 UplighTED studies evaluating efgartigimod for thyroid eye disease after an Independent Data Monitoring Committee recommended stopping the trials for futility, despite a favorable safety profile.

Denali Therapeutics appointed Tim Van Hauwermeiren to its Board of Directors and announced the departure of Chief Medical Officer Carole Ho to Eli Lilly, with Peter Chin assuming the Acting Chief Medical Officer role.

Belgian stocks closed higher on Monday, with the BEL 20 index rising 1.37%. The top performers were Galapagos NV, UCB SA, and D'Ieteren NV, while Proximus NV, Aperam SA, and Argen-X declined.

Cartesian Therapeutics announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis. The study achieved its primary endpoint, with 71% of MG patients treated with Descartes-08 showing significant improvements in MG Composite score compared to 25% with placebo.

These five biotech companies could have a lot of room to run.